RBBP9 and infectious otitis media: Consistent with enhanced inflammation in DSS-treated Rbbp9-/- mice (Figure 2), AOM/DSS-treated Rbbp9-/- tumors exhibited increased infiltration of immune cells, including CD45+ leukocytes and CD11b+ myeloid cells (Figure 3F and G), than the controls.